Ana L. Rodríguez-Perea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana L. Rodríguez-Perea has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Javier Diaz
Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
1 shared publication - Juan D. Cerón
Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
1 shared publication - Laura Milena Monsalve-Escudero
Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
1 shared publication - Maria Isabel Zapata-Cardona
Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
1 shared publication - Santiago Estrada
Laboratorio Clínico, Salud VID, Medellín, Colombia
1 shared publication - Wbeimar Aguilar-Jimenez
Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 46 (4) , 585-605
Characterization of a Colombian monkeypox virus isolate and exploratory evaluation of repurposed antiviral drugs
Introduction. Monkeypox cases have persisted in Colombia since the 2022 outbreak.Objective. To report the isolation and characterization of a monkeypox virus (MPXV) strain obtained from a Colombian patient during the 2022 outbreak, and to evaluate the antiviral potential of repurposed drugs against this isolate.Materials and methods. Lesion samples were inoculated into Vero-E6 cells. Viral isolation was characterized using virologic and molecular techniques. In addition, indirect immunofluorescence and neutralization assays were performed using convalescent serum. The antiviral activity of heparin, chloroquine, and ciprofloxacin was evaluated using a combined treatment strategy (multiplicity of infection = 2). Results. Cytopathic effect was observed 48 h post-infection. Viral titers reached 1.50 × 10⁶ PFU/ml. Phylogenetic analysis placed the isolate within clade IIb (B.1 lineage). Convalescent serum remained IFI-positive up to 1:160, and a 50% plaque reduction neutralization test of 35.6 was obtained. Chloroquine (50% inhibitory concentration ≈ 51.1 μM; selectivity index ≈ 2.2), heparin (50% inhibitory concentration ≈ 45.6 μg/ml; selectivity index ≈ 2.4), ciprofloxacin (50% inhibitory concentration ≈ 48.9 μM; selectivity index ≈ 3.9), and rifampicin (positive control; 50% inhibitory concentration ≈ 14.3 μM; selectivity index ≈ 19.7) significantly reduced MPXV infection. Molecular docking showed favorable binding of ciprofloxacin (-7.0 kcal/mol) and rifampicin (-7.2 kcal/mol) to the viral polymerase.Discussion. We successfully isolated and characterized an MPXV strain from a Colombian patient, establishing a platform for humoral and antiviral testing. Chloroquine, heparin, and ciprofloxacin showed measurable in vitro activity, supporting their potential for repurposing against this disease.
- 16 October 2026
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 46 (4) , 585-605
Open AccessCharacterization of a Colombian monkeypox virus isolate and exploratory evaluation of repurposed antiviral drugs
Introduction. Monkeypox cases have persisted in Colombia since the 2022 outbreak.Objective. To report the isolation and characterization of a monkeypox virus (MPXV) strain obtained from a Colombian patient during the 2022 outbreak, and to evaluate the antiviral potential of repurposed drugs against this isolate.Materials and methods. Lesion samples were inoculated into Vero-E6 cells. Viral isolation was characterized using virologic and molecular techniques. In addition, indirect immunofluorescence and neutralization assays were performed using convalescent serum. The antiviral activity of heparin, chloroquine, and ciprofloxacin was evaluated using a combined treatment strategy (multiplicity of infection = 2). Results. Cytopathic effect was observed 48 h post-infection. Viral titers reached 1.50 × 10⁶ PFU/ml. Phylogenetic analysis placed the isolate within clade IIb (B.1 lineage). Convalescent serum remained IFI-positive up to 1:160, and a 50% plaque reduction neutralization test of 35.6 was obtained. Chloroquine (50% inhibitory concentration ≈ 51.1 μM; selectivity index ≈ 2.2), heparin (50% inhibitory concentration ≈ 45.6 μg/ml; selectivity index ≈ 2.4), ciprofloxacin (50% inhibitory concentration ≈ 48.9 μM; selectivity index ≈ 3.9), and rifampicin (positive control; 50% inhibitory concentration ≈ 14.3 μM; selectivity index ≈ 19.7) significantly reduced MPXV infection. Molecular docking showed favorable binding of ciprofloxacin (-7.0 kcal/mol) and rifampicin (-7.2 kcal/mol) to the viral polymerase.Discussion. We successfully isolated and characterized an MPXV strain from a Colombian patient, establishing a platform for humoral and antiviral testing. Chloroquine, heparin, and ciprofloxacin showed measurable in vitro activity, supporting their potential for repurposing against this disease.